Erkang pharmaceutical expects the highest decline of net profit of 60% in 2018, and cancels over 250 million purchase and sale contracts

On January 30, the "2018 annual performance forecast" released by Erkang pharmaceutical showed that the expected net profit was RMB 208982500-313473800, down 40% - 60% year on year There are three main reasons for the decline: 1 Influenced by the pharmaceutical industry environment and industry policies, the sales volume of modified starch, starch capsule and other products produced by the company decreased compared with the same period of last year, and the sales revenue decreased significantly compared with the same period of last year 2 During the reporting period, the company increased its product marketing efforts, and the sales expenses in 2018 increased significantly compared with the same period last year 3 It is estimated that the impact of non recurring profit and loss on net profit during the reporting period is about - 42.5 million yuan, and the amount of non recurring profit and loss is about 101.39 million yuan less than that of the same period last year, mainly due to the increase of non operating expenditure caused by the expected liabilities in the case of Securities Misrepresentation liability dispute and the payment of fines by subsidiaries On the same day, Erkang pharmaceutical also issued a notice on signing the agreement on termination of purchase and sale of hydroxypropyl starch hollow capsules, which shows that Erkang pharmaceutical signed the agreement on purchase and sale of hydroxypropyl starch hollow capsules with IKO pharmaceutical on March 15, 2018, and IKO pharmaceutical purchased 8.8 billion hydroxypropyl starch hollow capsules from the company, with a total amount of 265 million yuan Now, due to the impact of changes in national policies, the actual procurement situation of Yike Pharmaceutical Co., Ltd has been unable to continue to perform according to the purchase and sale agreement After friendly consultation, both parties decided to sign the termination agreement Up to now, Erkang pharmaceutical has sold 836 million hydroxypropyl starch hollow capsules to IKO pharmaceutical and its related parties The original texts of the two announcements are as follows: